This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Law Office Of Robbins Umeda LLP Announces The Filing Of A Class Action Suit Against AspenBio Pharma, Inc.

Robbins Umeda LLP today announced that a class action has been commenced in the U.S. District Court for the Central District of California, Western Division (the "Court") on behalf of purchasers of AspenBio Pharma, Inc. ("AspenBio" or the "Company") (NASDAQ: APPY) common stock during the period between February 22, 2007 and July 19, 2010 (the "Class Period").

AspenBio is a bio-pharmaceutical company that engages in the discovery, development, and commercialization of products that address unmet diagnostic and therapeutic needs. The Company's research and development focus mainly on a human appendicitis blood based test and a bovine single-chain recombinant reproduction enhancement drug. The Company's lead product, AppyScore, is, according to the Company, a rapid blood-based diagnostic test to assist physicians in the diagnosis of acute appendicitis in the hospital emergency department setting. The Company was founded in 2000 and is headquartered in Castle Rock, Colorado.

The complaint alleges that AspenBio and certain of its officers issued materially false and misleading statements during the Class Period about the effectiveness of AppyScore and failed to acknowledge that AppyScore could not differentiate between appendicitis and other medical conditions.

During 2007, AspenBio released multiple press releases announcing the clinical results from the ongoing research of AppyScore, which would purportedly aid emergency room staff in the diagnosis of appendicitis in humans. In November 2007, AspenBio announced that it would pursue a 501(k) regulatory clearance from the U.S. Food and Drug Administration ("FDA") for AppyScore, and expected to receive clearance before the end of 2008. Throughout 2009, via public press releases and U.S. Securities and Exchange Commission filings, AspenBio continued to advertise the effectiveness and high sensitivity of AppyScore to detecting patients with a wide spectrum of different severities of appendicitis. Following these and related statements, the price of AspenBio stock rose substantially.

Then, on June 7, 2010, the Company disclosed there was "unexplained variability" in the test results of its most recent clinical trial for AppyScore. Furthermore, on July 19, 2010, AspenBio reported the results from its clinical trial, and announced that AppyScore possessed considerably lower specificity of identifying appendicitis than predicted. As a result of these disclosures, the Company's stock declined approximately 29% from its close price of $0.97 on July 19, 2010, to close at $0.69 per share on July 20, 2010.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,672.60 -141.38 -0.79%
S&P 500 2,051.82 -11.33 -0.55%
NASDAQ 4,757.8790 +7.4820 0.16%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs